Company intelligence / Profile preview
EyePoint Pharmaceuticals
Watertown, Massachusetts, USAeyepointpharma.com ↗
- Ownership
- Public · EYPT
- Employees
- ~165
- Development stage
- Phase 3
01
Overview
EyePoint’s lead candidate DURAVYU™ (formerly EYP‑1901) has shown positive safety and efficacy in Phase 1 and topline Phase 2 trials for wet AMD. The company expects to initiate pivotal Phase 3 trials in wet AMD in 2024. Its sustained-release platform has been validated with four FDA-approved products historically. DEXYCU® was approved for post-surgical inflammation but the company now focuses on retina indications.
- Therapeutic areas
- Ophthalmology
- Modalities
- sustained-release drug delivery systemssmall molecules (notably tyrosine kinase inhibitors)injectable implants
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Equinox Sciences/Betta Pharmaceuticals – exclusive license for vorolanib outside China/Macao/Hong Kong/TaiwanQinetiQ – strategic partner on porous silicon technologyAlimera Sciences – past partnership on Iluvien productHarrow Health – alliance related to DEXYCU commercialization
04
Financials
- Market cap
- $29.8M
- Total revenue
- $31.4M
- Enterprise value
- $-128.3M
Beyond the preview
Go deeper on EyePoint Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EyePoint Pharmaceuticals.